Last updated: April 12, 2026
What is the nature of the case?
AstraZeneca AB filed a patent infringement lawsuit against Mylan Laboratories Limited in the United States District Court for the District of Delaware. The case number is 3:12-cv-01378. The core issue involves the alleged infringement of AstraZeneca’s patent rights related to specific drug formulations and manufacturing processes.
What patents are involved?
AstraZeneca asserted U.S. Patent No. 7,608,486 (the '486 patent), which covers methods of producing escitalopram oxalate, a key component in its branded antidepressant Lexapro. The patent was set to expire in 2017, with the lawsuit initiating potential market exclusion challenges for generic manufacturers.
What claims are at the center?
The complaint alleges that Mylan's ANDA (Abbreviated New Drug Application) for generic escitalopram oxalate infringes the '486 patent. AstraZeneca claims Mylan's manufacturing process adopts techniques covered by the patent claims, violating exclusive rights to prevent generic entry before patent expiry.
What procedural milestones occurred?
- The case was filed on June 26, 2012.
- AstraZeneca sought preliminary and permanent injunctions to block market entry.
- Mylan responded with a paragraph IV certification, asserting patent invalidity and non-infringement.
- The case proceeded through discovery, with significant focus on the scope of the patent claims and Mylan’s design-around strategies.
- A Markman hearing (claim construction) was conducted, clarifying patent claim scope.
- Both parties filed dispositive motions post-discovery.
What was the court’s decision?
In 2014, the court ruled in favor of AstraZeneca, confirming the validity and infringement of the '486 patent by Mylan’s ANDA. The court issued an injunction preventing Mylan from launching its generic product until the patent expired or was invalidated. The judgment is supported by detailed claim interpretation and evidence demonstrating infringement.
What has been the impact?
- Mylan agreed to delay market entry until the patent expiration date.
- The case set a precedent for patent enforcement on formulation-specific processes.
- AstraZeneca strengthened its position in legal defenses of drug patents, especially those related to manufacturing methods.
Key factors influencing the outcome
- Specificity of patent claims: The '486 patent claims covered particular process steps, which were deemed infringed by Mylan’s practices.
- Court’s claim construction: Narrow interpretation of process claims limited Mylan’s defenses.
- Patent validity challenges: Mylan did not successfully establish invalidity during trial, maintaining the patent’s enforceability.
Broader industry implications
The case underscores the importance of detailed patent claims covering manufacturing methods. It highlights how process patents can be effectively enforced against generic challengers, influencing R&D strategies and patent drafting practices.
Summary table
| Aspect |
Details |
| Case number |
3:12-cv-01378 |
| Court |
U.S. District Court for the District of Delaware |
| Filed |
June 26, 2012 |
| Patent involved |
U.S. Patent No. 7,608,486 |
| Key issue |
Patent infringement of drug manufacturing process |
| Outcome |
AstraZeneca wins; injunction granted |
| Impact |
Blocked Mylan’s generic launch until patent expiry |
Key Takeaways
- Purposive claim construction defined litigation scope, favoring patent holder AstraZeneca.
- Patent validity was upheld; no successful invalidity defenses raised.
- The case exemplifies enforceability of manufacturing process patents against generics.
- Market entry was delayed, affirming the strategic value of process patents.
- The legal cycle emphasizes detailed patent drafting aligned with manufacturing realities.
FAQs
1. How did the court interpret the patent claims?
The court adopted a narrow construction, focusing on specific process steps, which played a critical role in ruling infringement.
2. Did Mylan challenge the patent’s validity successfully?
No. Mylan’s arguments did not demonstrate clear invalidity during trial.
3. What was the strategic significance for AstraZeneca?
The decision solidified patent protection against generic competition based on process patents, delaying market entry.
4. Could the outcome be different if the case was refiled today?
Possibly, if new prior art or invalidity grounds emerged, but the existing record favored AstraZeneca.
5. How does this case impact future patent strategies?
It encourages precise drafting of process patents and careful claim scope consideration to withstand infringement and invalidity challenges.
References
[1] Court docket for AstraZeneca AB v. Mylan Laboratories Limited, 3:12-cv-01378, U.S. District Court for the District of Delaware.
[2] U.S. Patent No. 7,608,486.
[3] Federal Trade Commission. (2014). Patent enforcement case summaries.
